Press Releases
enVVeno Medical to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ETIRVINE, CA / November 16, 2021 / enVVeno Medical Corporation (Nasdaq:NVNO)...
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Quarter marked by corporate rebranding and strategic prioritization of development programs- Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency...
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI)Severe CVI Impacts Approximately 2.4 million U.S. Patients with No Current Effective Treatment OptionsIRVINE,...
enVVeno Medical Corporation Successfully Completes Rebranding
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully...
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a...
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® -- Initiated development of second product for the...
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and...
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
IRVINE, CA / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a...
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectivelyPatients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrencesNo safety issues occurred during...
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe’s VenoValve
- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions- Company preparing to begin SAVVE U.S. pivotal trial for VenoValve- VenoValve is a potential...